Grassley Hounds DOJ on Whether Mylan Settlement Is ‘Reasonable’

Sen. Charles Grassley (R-Iowa) wants the Department of Justice to provide details on a settlement Mylan reached to resolve claims that the company misclassified its epinephrine auto-injector EpiPen for the Medicaid Drug Rebate program.

In a letter to Attorney General Loretta Lynch, Grassley calls on the department to be more transparent about the agreement it reached with the company, noting that very few details have emerged on the $465 million settlement.

According to Mylan, the settlement requires that the EpiPen be categorized as a name-brand product under the drug rebate program starting in April 2017. In his letter, Grassley specifically asks Lynch to explain why this reclassification won’t take effect immediately.